▲ Peaking
Business
Novartis to Buy Myricx Bio for Up to $1.5 Billion
Novartis is acquiring UK-based Myricx Bio in a deal valued at up to $1.5 billion to expand its cancer-drug pipeline.
1 trends tracked about this subject — the full history, oldest to newest below.
Novartis is acquiring UK-based Myricx Bio in a deal valued at up to $1.5 billion to expand its cancer-drug pipeline.